Molecular diagnostics is the fastest-growing segment of the IVD market, projected to register a CAGR of 14.5% from 2025 to 2030. The COVID-19 pandemic permanently expanded molecular diagnostic infrastructure globally — laboratories that installed PCR platforms for COVID testing are now expanding menus to respiratory syndromic panels, STI testing, and oncology applications. Next-generation sequencing is advancing from research toward clinical routine in oncology somatic mutation testing, germline hereditary cancer testing, and pharmacogenomics. Cepheid's GeneXpert platform has over 50,000 installed instruments globally. Abbott's ID NOW received CE marking for its 2.0 enhanced platform in January 2025. Syndromic testing panels — simultaneously detecting multiple pathogens from a single sample — are reducing sequential testing and shortening time to clinical decision.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Molecular Diagnostics Market Size and Forecast 2025-2030 by Technology and Application
• PCR — Real-Time PCR, Digital PCR, and Multiplex PCR Market Dynamics
• Syndromic Panels — Respiratory, GI, Meningitis/Encephalitis, and Blood Culture
• Next-Generation Sequencing — Oncology, Infectious Disease, and Rare Disease Applications
• CRISPR-Based Diagnostics — Technology Status and Emerging Commercial Applications
• Point-of-Care Molecular — GeneXpert, ID NOW, and Near-Patient Molecular Testing
• Liquid Biopsy Molecular — ctDNA, cfRNA, and Multi-Cancer Early Detection
• Competitive Landscape — Roche, Cepheid, Abbott, Hologic, bioMérieux, and Challengers
• Investment and Partnership Opportunities